Recombinant human protein was used as the immunogen for this DOG1 antibody.
Expression of TMEM16A (DOG1) protein is elevated in the gastrointestinal stromal tumors (GISTs), c-kit signaling-driven mesenchymal tumors of the GI tract. It is rarely expressed in other soft tissue tumors, which, due to appearance, may be difficult to diagnose. Immunoreactivity for DOG11 has been reported in 97.8 percent of scorable GISTs, including all c-kit negative GISTs. Overexpression has been suggested to aid in the identification of GISTs, including Platelet-Derived Growth Factor Receptor Alpha (PDGFR alpha) mutants that fail to express c-kit antigen. The overall sensitivity of TMEM16A and c-kit in GISTs is nearly identical: 94.4% vs. 94.7%.
Clonality:
Monoclonal
Concentration:
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide, *For IHC use only*
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide, *For IHC use only*
Purity:
Protein G affinity chromatography
Form:
Prediluted in 1X PBS, 0.1 mg/ml BSA (US sourced), 0.05% sodium azide, *For IHC use only*
Target:
DOG1
Antibody Type:
Primary Antibody
Application Dilute:
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Application Notes:
Titering of the DOG1 antibody may be required for optimal performance.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
